MEDICAL SERVICES

Specialties

Departments

Programs

Languages

  • English

EDUCATION

Graduate Degree

  • University of Arkansas , 1978 , Little Rock , AR

Medical School

  • University of Arkansas College of Medicine , 1983 , Little Rock , AR

Internship

  • Arkansas Children's Hospital , 1984 , Little Rock , AR

Residency

Pediatrics
  • Arkansas Children's Hospital , 1985 , Little Rock , AR

Fellowship

Pediatric Infectious Diseases
  • Children's Hospital and Medical Center , 1989 , Seattle , WA

CERTIFICATIONS

  • American Board of Pediatrics, Infectious Diseases

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Labuda SM, Huo Y, Kacanek D, Patel K, Huybrechts K, Jao J, Smith C, Hernandez-Diaz S, Scott G, Burchett S, Kakkar F, Chadwick EG, Van Dyke RB. Rates of Hospitalization and Infection-Related Hospitalization Among Human Immunodeficiency Virus (HIV)-Exposed Uninfected Children Compared to HIV-Unexposed Uninfected Children in the United States, 2007-2016. Clin Infect Dis. 2020 Jul 11; 71(2):332-339. View abstract
  2. Jao J, Kacanek D, Yu W, Williams PL, Patel K, Burchett S, Scott G, Abrams EJ, Sperling RS, Van Dyke RB, Smith R, Malee K. Neurodevelopment of HIV-Exposed Uninfected Infants Born to Women With Perinatally Acquired HIV in the United States. J Acquir Immune Defic Syndr. 2020 06 01; 84(2):213-219. View abstract
  3. Eke AC, Wang J, Amin K, Shapiro DE, Stek A, Smith E, Chakhtoura N, Basar M, George K, Knapp KM, João EC, Rungruengthanakit K, Capparelli E, Burchett S, Mirochnick M, Best BM. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. Antimicrob Agents Chemother. 2020 03 24; 64(4). View abstract
  4. Attia EF, Jacobson D, Yu W, Crowell CS, Maleche-Obimbo E, Williams PL, West TE, Burchett SK, Kattan M, Colin AA, Eskander S, Chung MH, Crothers K, Shearer WT. Immune imbalance and activation are associated with lower lung function in youth with perinatally acquired HIV. J Allergy Clin Immunol. 2020 May; 145(5):1473-1476. View abstract
  5. Purswani MU, Russell JS, Dietrich M, Malee K, Spector SA, Williams PL, Frederick T, Burchett S, Redmond S, Hoffman HJ, Torre P, Lee S, Rice ML, Yao TJ. Birth Prevalence of Congenital Cytomegalovirus Infection in HIV-Exposed Uninfected Children in the Era of Combination Antiretroviral Therapy. J Pediatr. 2020 01; 216:82-87.e2. View abstract
  6. Patel K, Seage GR, Burchett SK, Hazra R, Van Dyke RB. Disparities in HIV Viral Suppression Among Adolescents and Young Adults by Perinatal Infection. Am J Public Health. 2019 07; 109(7):e9. View abstract
  7. Ben Farhat K, Alosaimi MF, Shendi H, Al-Hammadi S, Jones J, Schwarz K, Schulz A, Alawdah LS, Burchett S, Albuhairi S, Whangbo J, Kwatra N, Shamseldin HE, Alkuraya FS, Chou J, Geha RS. Immunologic reconstitution following hematopoietic stem cell transplantation despite lymph node paucity in NF-?B-inducing kinase deficiency. J Allergy Clin Immunol. 2019 03; 143(3):1240-1243.e4. View abstract
  8. Momper JD, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Badell ML, Acosta EP, Purswani M, Smith E, Chakhtoura N, Park K, Burchett S, Shapiro DE, Mirochnick M. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018 11 13; 32(17):2507-2516. View abstract
  9. Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E, Chakhtoura N, Burchett S, Mirochnick M. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018 03 27; 32(6):729-737. View abstract
  10. Jao J, Kacanek D, Williams PL, Geffner ME, Livingston EG, Sperling RS, Patel K, Bardeguez AD, Burchett SK, Chakhtoura N, Scott GB, Van Dyke RB, Abrams EJ. Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol. Clin Infect Dis. 2017 Sep 15; 65(6):982-989. View abstract
  11. Hay S, Burchett S, Odejide O, Cataltepe S. Septic Episodes in a Premature Infant After In Utero Exposure to Rituximab. Pediatrics. 2017 Sep; 140(3). View abstract
  12. Neilan AM, Karalius B, Patel K, Van Dyke RB, Abzug MJ, Agwu AL, Williams PL, Purswani M, Kacanek D, Oleske JM, Burchett SK, Wiznia A, Chernoff M, Seage GR, Ciaranello AL. Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth. JAMA Pediatr. 2017 05 01; 171(5):450-460. View abstract
  13. Huo Y, Patel K, Scott GB, Van Dyke RB, Siberry GK, Burchett SK, Shearer WT. Lymphocyte subsets in HIV-exposed uninfected infants and HIV-unexposed uninfected infants. J Allergy Clin Immunol. 2017 08; 140(2):605-608.e3. View abstract
  14. Gauguet S, Madden K, Wu J, Duncan C, Lee GS, Miller T, Klingensmith WC, Burchett SK, van der Velden M. Case Report of a Child after Hematopoietic Cell Transplantation with Acute Aspergillus Tracheobronchitis as a Cause for Respiratory Failure. Case Rep Pediatr. 2016; 2016:9676234. View abstract
  15. Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. . 2016 07 01; 72(3):289-96. View abstract
  16. Agwu AL, Yao TJ, Eshleman SH, Patel K, Huang W, Burchett SK, Siberry GK, Van Dyke RB. Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy. Pediatr Infect Dis J. 2016 07; 35(7):777-81. View abstract
  17. Van Dyke RB, Patel K, Kagan RM, Karalius B, Traite S, Meyer WA, Tassiopoulos KK, Seage GR, Seybolt LM, Burchett S, Hazra R, Lurie RH, Yogev R, Sanders MA, Malee K, Hunter S, Shearer W, Paul M, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Garvie P, Blood J, Burchett S, Karthas N, Kammerer B, Wiznia A, Burey M, Nozyce M, Dieudonne A, Bettica L, Adubato S, Chen J, Bulkley MG, Ivey L, Grant M, Knapp K, Allison K, Wilkins M, Acevedo-Flores M, Rios H, Olivera V, Silio M, Jones M, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Katai A, Dunn J, Paul S, Scott G, Bryan P, Willen E. Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV. Clin Infect Dis. 2016 07 01; 63(1):133-137. View abstract
  18. Gantt S, Leister E, Jacobsen DL, Boucoiran I, Huang ML, Jerome KR, Jourdain G, Ngo-Giang-Huong N, Burchett S, Frenkel L. Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy. J Med Virol. 2016 Jun; 88(6):1051-8. View abstract
  19. Purswani MU, Karalius B, Yao TJ, Schmid DS, Burchett SK, Siberry GK, Patel K, Van Dyke RB, Yogev R, Lurie RH, Yogev R, Sanders MA, Malee K, Hunter S, Shearer W, Paul M, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Garvie P, Blood J, Burchett S, Karthas N, Kammerer B, Wiznia A, Burey M, Nozyce M, Dieudonne A, Bettica L, Adubato S, Chen J, Bulkley MG, Ivey L, Grant M, Knapp K, Allison K, Wilkins M, Acevedo-Flores M, Rios H, Olivera V, Silio M, Jones M, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Katai A, Dunn J, Paul S, Scott G, Bryan P, Willen E. Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. Clin Infect Dis. 2016 Jan 01; 62(1):106-114. View abstract
  20. Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, Cressey TR, Mofenson LM, Smith E, Shapiro D, Mirochnick M. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. . 2015 Sep 01; 70(1):33-41. View abstract
  21. Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clin Infect Dis. 2015 Nov 15; 61(10):1582-9. View abstract
  22. Siberry GK, Patel K, Bellini WJ, Karalius B, Purswani MU, Burchett SK, Meyer WA, Sowers SB, Ellis A, Van Dyke RB. Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection. Clin Infect Dis. 2015 Sep 15; 61(6):988-95. View abstract
  23. Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11. View abstract
  24. Kapetanovic S, Aaron L, Montepiedra G, Anthony P, Thuvamontolrat K, Pahwa S, Burchett S, Weinberg A, Kovacs A. Effect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy. PLoS One. 2015; 10(3):e0120474. View abstract
  25. Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M. Raltegravir pharmacokinetics during pregnancy. . 2014 Dec 01; 67(4):375-81. View abstract
  26. Persaud D, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Ellis A, Chen YH, Richman D, Siberry GK, Van Dyke RB, Burchett S, Seage GR, Luzuriaga K. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr. 2014 Dec; 168(12):1138-46. View abstract
  27. Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med. 2015 Mar; 16(3):176-83. View abstract
  28. Schwenk H, Ramirez-Avila L, Sheu SH, Wuthrich C, Waugh J, Was A, Degirolami U, Burchett S, Koralnik IJ, Ahmed A. Progressive multifocal leukoencephalopathy in pediatric patients: case report and literature review. Pediatr Infect Dis J. 2014 Apr; 33(4):e99-105. View abstract
  29. Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, Renna H, Lu Y. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jun; 19(7):1441-9. View abstract
  30. Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. . 2013 May 01; 63(1):59-66. View abstract
  31. Lo MS, Lee GM, Gunawardane N, Burchett SK, Lachenauer CS, Lehmann LE. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013 Mar; 17(2):133-43. View abstract
  32. Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A. Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis. 2012 Aug 01; 206(3):421-30. View abstract
  33. Kapetanovic S, Aaron L, Montepiedra G, Burchett SK, Kovacs A. T-cell activation and neurodevelopmental outcomes in perinatally HIV-infected children. AIDS. 2012 May 15; 26(8):959-69. View abstract
  34. Miller TI, Borkowsky W, DiMeglio LA, Dooley L, Geffner ME, Hazra R, McFarland EJ, Mendez AJ, Patel K, Siberry GK, Van Dyke RB, Worrell CJ, Jacobson DL, Shearer W, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Patton D, Burchett S, Karthas N, Kammerer B, Yogev R, Malee K, Hunter S, Cagwin E, Wiznia A, Burey M, Nozyce M, Chen J, Gobs E, Grant M, Knapp K, Allison K, Garvie P, Acevedo-Flores M, Rios H, Olivera V, Silio M, Borne C, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Barr E, Chambers C, Watson D, Messenger N, Belanger R, Dieudonne A, Bettica L, Adubato S, Scott G, Himic L, Willen E. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012 May; 13(5):264-75. View abstract
  35. Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, Li H, Read JS, Jennings A, Barr E, Smith E, Rossi SS, Mirochnick M. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012 Apr; 13(4):226-35. View abstract
  36. Ehlinger EP, Webster EM, Kang HH, Cangialose A, Simmons AC, Barbas KH, Burchett SK, Gregory ML, Puopolo KM, Puopolo KP, Permar SR. Maternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infants. J Infect Dis. 2011 Dec 01; 204(11):1672-82. View abstract
  37. Siberry GK, Patel K, Van Dyke RB, Hazra R, Burchett SK, Spector SA, Paul ME, Read JS, Wiznia A, Seage GR. CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. . 2011 Jul 01; 57(3):223-9. View abstract
  38. Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, Read JS, Mofenson LM, Seage GR. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. . 2011 Jun 01; 57(2):165-73. View abstract
  39. Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. . 2011 Apr 15; 56(5):412-9. View abstract
  40. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 2011 Apr 15; 52(8):1003-9. View abstract
  41. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. . 2010 Aug; 54(4):381-8. View abstract
  42. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. . 2010 Jul; 54(3):285-9. View abstract
  43. Brogly SB, Foca M, Deville JG, Mirochnick M, Scott GB, Mofenson LM, Read JS, Viani RM, Burchett SK, Cooper ER, Browning R, Shapiro DE. Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. . 2010 Jan; 53(1):154-7. View abstract
  44. Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010 Apr; 11(4):232-8. View abstract
  45. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. . CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1-Infected Children Receiving Highly Active Antiretroviral Therapy. . J Acquir Immune Defic Syndr. . 2009. View abstract
  46. Kamin DS, Burchett S, Kim HB. Case 15-2009: a man with coma after cardiac arrest. N Engl J Med. 2009 Aug 13; 361(7):725; author reply 725. View abstract
  47. Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009 Feb; 104(2):444-53. View abstract
  48. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS. Lopinavir exposure with an increased dose during pregnancy. . 2008 Dec 15; 49(5):485-91. View abstract
  49. Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett SK, Smith ME, Sheeran EC, Shearer WT, Febo I, Mirochnick M. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008 Nov; 9(10):875-82. View abstract
  50. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008 Apr; 9(4):214-20. View abstract
  51. Brookie Best, A Stek, C Hu, S Burchett, S Rossi, E Smith, B Sheeran, J Read, E Capparelli, and M Mirochnick for the PACTG/IMPAACT P1026s Team. High-dose Lopinavir and Standard-dose Emtricitabine Pharmacokinetics during Pregnancy and Postpartum. 15th Conference on Retroviruses and Opportunistic Infections. 2008; 629. View abstract
  52. Akihiko Saitoh, E Sarles, E Capparelli, F Aweeka, A Kovacs, S Burchett, A Wiznia, S Nachman, T Fenton, and S Spector. CYP2C19 Genetic Variants Affect Nelfinavir and M8 Pharmacokinetics and Virologic Response in HIV-1 Infected Children Receiving HAART. 15th Conference on Retroviruses and Opportunistic Infections. 2008; 572. View abstract
  53. Handelsman E, Cheng I, Thompson B, Hershow R, Mofenson LM, Hollinger FB, Chen KT, Burchett SK, Klinzman D, Stapleton JT. Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. HIV Med. 2007 Nov; 8(8):561-7. View abstract
  54. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 Oct 18; 21(16):2191-9. View abstract
  55. Burchett SK and Dalgic N. Viral Infections. Manual of Neonatal Care, Cloherty, Eichenwald, Stark, eds. 2007. View abstract
  56. Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet. 2007 Jul 07; 370(9581):68-80. View abstract
  57. Jennifer Read, B Best, A Stek, C Hu, E Capparelli, D Holland, S Burchett, E Smith, B Sheeran and M Mirochnick. Nelfinavir Pharmacokinetics (625-mg Tablets) during the Third Trimester of Pregnancy and Post-partum. 14th Conference on Retroviruses and Opportunistic Infections. 2007; 740. View abstract
  58. Sandra Burchett, B Bestm M Mirochnick, C Hu, E Capparelli, C Fletcher, E Smith, B Sheeran, J Read, A Stek, for the PACTG 1026s Team. Tenofovir Pharmacokinetics during Pregnancy, at Delivery and Postpartum. 14th Conference on Retroviruses and Opportunistic Infections. 2007; 738b. View abstract
  59. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. Reduced lopinavir exposure during pregnancy. AIDS. 2006 Oct 03; 20(15):1931-9. View abstract
  60. Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006 Feb 28; 20(4):553-60. View abstract
  61. M Mirochnick, A Stek, E Capparelli, B Best, D Holland, J Connor, SK Burchett, et al. . Lopinavir exposure with a higher dose during the 3rd trimester of pregnancy. 13th Conference on Retroviruses and Opportunistic Infections. 2006. View abstract
  62. Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, Capparelli E, Mofenson L, Smith E, McIntosh K, Burchett SK. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J of Infec Disease. 2005; 192(2):296-302. View abstract
  63. Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, Yu XG, Verrill C, Allen T, Moore C, Mallal S, Burchett S, McIntosh K, Pelton SI, St John MA, Hazra R, Klenerman P, Altfeld M, Walker BD, Goulder PJ. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol. 2005 Jun 15; 174(12):7524-30. View abstract
  64. Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, Capparelli E, Mofenson L, Smith E, McIntosh K, Burchett SK. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis. 2005 Jul 15; 192(2):296-302. View abstract
  65. Weinberg G and Burchett SK . Pediatric Human Immunodeficiency Virus Infection. Principles and Practice of Infectious Diseases, Mandell G, Bennett J, Dolin R, eds. 2005; 1638-54. View abstract
  66. Wade NA, Unadkat JD, Huang S, Shapiro DE, Mahias A, Yasin S, Ciupak G, Watts DH, Delke I, Rathore M, Hitti J, Frenkel L, Samelson R, Smith ME, Mofenson L, Burchett SK . Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: pediatric AIDS clinical trials group protocol 332. Journal of Infectious Diseases . 2004; 190(12):2167-74. View abstract
  67. Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, Yasin S, Ciupak G, Watts DH, Delke I, Rathore M, Hitti J, Frenkel L, Samelson R, Smith ME, Mofenson L, Burchett SK. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis. 2004 Dec 15; 190(12):2167-74. View abstract
  68. Stek A, Mirochnick M, Capparelli E, Best B, Burchett S, et al. PACTG 1026 team . Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. International AIDS Conference. 2004; Bangkok. View abstract
  69. Weinberg A, Pahwa S, Oyomopito R, Carey VJ, Zimmer B, Mofenson L, Kovacs A, Burchett SK. Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004 Jul 01; 39(1):107-14. View abstract
  70. Shapiro D, Tuomala R, Pollack H, Burchett S, Read J, Cababasay M, McNamara J, Ciupak G . Mother-to child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 US women (PACTG 367). 11th Conference on Retroviruses and Opportunistic Infections. 2004; San Francisco:A99. View abstract
  71. Weinberg A, Pahwa S, Oyomopito R, Carey VJ, Zimmer B, Mofenson L, Kovacs A, Burchett SK, Pediatric AIDS Clinical Trials Group 366 Team . Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clinical Infectious Diseases . 2004; 39(1):107-14. View abstract
  72. Soh CH, Oleske JM, Brady MT, Spector SA, Borkowsky W, Burchett SK, Foca MD, Handelsman E, Jiménez E, Dankner WM, Hughes MD. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003 Dec 20; 362(9401):2045-51. View abstract
  73. Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol. 2003 Dec 15; 171(12):6968-75. View abstract
  74. Burchett SK and Pizzo PA . HIV Infection in Infants, Children, and Adolescents. Pediatrics in Review. 2003; 24:186-93. View abstract
  75. Feeney ME, Roosevelt KA, Tang Y, Pfafferott KJ, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ. Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children. J Virol. 2003 Jul; 77(13):7492-501. View abstract
  76. Burchett SK, Pizzo PA. HIV infection in infants, children, and adolescents. Pediatr Rev. 2003 Jun; 24(6):186-94. View abstract
  77. Burchett SK . Congenital Infections. Manual of Pediatric Practice, Finberg L, editor. 2003. View abstract
  78. Burchett SK . Viral Infections. Manual of Neonatal Care, Cloherty JP and Stark AR, editors. 2003; 255-86. View abstract
  79. Wade N, Unadkat J, Huang S, Shapiro D, Yasin S, Mathias A, Samelson R, Bryson Y, Mofenson L, Watts H, Smith M, Burchett S. Pharmakokinetics and Safety of d4T and 3TC in HIV-infected Pregnant Women and Their Infants (PACTG 332). 10th Conference on Retroviruses and Opportunistic Infections. 2003; Boston:A886. View abstract
  80. Feeney ME, Day CL, Roosevelt KA, McIntosh K, Burchett S, et al. . Robust Gag-specific T-helper Response Associated with Viral Control in Pediatric HIV Infection. 10th Conference on Retroviruses and Opportunistic Infections. 2003; Boston:A299. View abstract
  81. Burchett SK and Pizzo PA . HIV Infection in Infants, Children, and Adolescents. Pediatrics in Review. 2003; 24:186-194. View abstract
  82. Burchett SK . Perinatal Infections. Saunders Manual of Pediatric Practice, Finberg L. and Kleinman RE, editors. 2002; 356-61. View abstract
  83. Shapiro D, Tuomala R, Samelson R, Burchett S, Ciupak G, McNamara J, Pollard H, Read J . Mother-to-Child HIV Transmission Rates According to Antiretroviral Therapy, Mode of Delivery and Viral Load (PACTG 367). 9th Conference on Retroviruses and Opportunistic Infections. 2002; Seattle:A114. View abstract
  84. Working Group. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Health Services/Technology Assessment Text. 2001. View abstract
  85. Goulder PJ, Pasquier C, Holmes EC, Liang B, Tang Y, Izopet J, Saune K, Rosenberg ES, Burchett SK, McIntosh K, Barnardo M, Bunce M, Walker BD, Brander C, Phillips RE. Mother-to-child transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation. Immunol Lett. 2001 Nov 01; 79(1-2):109-16. View abstract
  86. McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, Frenkel LM, Yogev R, Gigliotti F, Luzuriaga K, Livingston RA. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis. 2001 Nov 15; 184(10):1331-5. View abstract
  87. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M, He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIntosh K, Korber BT, Walker BD. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature. 2001 Jul 19; 412(6844):334-8. View abstract
  88. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001 May; 107(5):E77. View abstract
  89. Frenkel LM, Burchett SK, Aldrovandi GM, et al. HIV-1 Reverse Transcriptase M184V/I Improves the Rate of Suppression of Viral Replication by Salvage Therapy. 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A463. View abstract
  90. Kovacs A, Burchett S, Khoury M, et al. . Virologic and Immunologic Responses in Children with Advanced HIV Disease on a New HAART Regimen (PACTG 366). 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A684. View abstract
  91. Weinberg A, Kovacs A, Pahwa S, Carey V, Oyomopito R, Mofenson L, Khoury M, Zimmer B, Burchett S. HIV-Infected Children on HAART Reconstitute Tetanus-Specific T Cell Responses without Booster Vaccination. 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A688. View abstract
  92. Goulder PJ, Jeena P, Tudor-Williams G, Burchett S. Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. Br Med Bull. 2001; 58:89-108. View abstract
  93. McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, Frenkel LM, Yogev R, Gigliotti F, Luzuriaga K, Livingston RA . Human immunodeficiency virus type 1 (HIV-1) gp 120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. Journal Infectious Diseases. 2001; 184:1331-5. View abstract
  94. Goulder PJ, Jeena P, Tudor-Williams G, Burchett S . Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. British Medical Bulletin . 2001; 58:89-108. View abstract
  95. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL . The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics . 2001; 107:E77. View abstract
  96. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL . The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. International Journal of STD and AIDS . 2001; 12:767. View abstract
  97. Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O'Callaghan CA, Kalams SA, McKinney RE, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med. 2000 Dec 18; 192(12):1819-32. View abstract
  98. Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A, Culnane M, Read JS, Thompson M, Mohan KM, Shaver A, Robinson CA, Stempien MJ, Burchett SK, Melvin AJ, Borkowsky W, Petru A, Kovacs A, Yogev R, Goldsmith J, McFarland EJ, Spector SA. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J Infect Dis. 2000 Dec; 182(6):1616-24. View abstract
  99. Lindsey JC, Hughes MD, McKinney RE, Cowles MK, Englund JA, Baker CJ, Burchett SK, Kline MW, Kovacs A, Moye J. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis. 2000 Nov; 182(5):1385-93. View abstract
  100. Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang Y, He S, Hartman KE, O'Callaghan CA, Ogg GS, Altfeld MA, Rosenberg ES, Cao H, Kalams SA, Hammond M, Bunce M, Pelton SI, Burchett SA, McIntosh K, Coovadia HM, Walker BD. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol. 2000 Jun; 74(12):5679-90. View abstract
  101. Hughes WT, Shenep JL, Rodman JH, Fridland A, Willoughby R, Blanchard S, Purdue L, Coakley DF, Cundy KC, Culnane M, Zimmer B, Burchett S, Read JS. Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group. Antimicrob Agents Chemother. 2000 Apr; 44(4):1041-6. View abstract
  102. Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D, Bryson Y, Burchett S, Spector SA, Frenkel LM, Starr S, Van Dyke R, Jimenez E. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis. 2000 Mar; 181(3):890-6. View abstract
  103. Burchett SK, Khoury M, McIntosh K, Carey SV, Oyomopito R, Mofenson L, Smith E, Kovacs A . Viral load reduction (VLR) in children with advanced HIV disease treated with 4-drug antiretroviral treatment (ART) regimens including NRTIs, Nevirapine (NVP), Nelfinavir (NFV), and/or Ritonavir (RTV):PACTG 366. 7th Conference on Retroviruses and Opportunistic Infections. 2000; San Francisco:A698. View abstract
  104. Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, Wara D, Bryson YJ, Starr SE, Petru A, Burchett S. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis. 2000 Feb; 181(2):548-54. View abstract
  105. Tuomala R, Shapiro D, Samelson R, Burchett S, Cuipak G, McNamara J, Pollack H, Read J . Antepartum antiretroviral therapy and viral load in 464 HIV-infected women in 1998-1999 (PACTG 367). American Journal of Obstetrics and Gynecology. 2000; 182:S99. View abstract
  106. Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly RP, Kalams SA, Burchett SK, McIntosh K, Walker BD, Goulder PJ . Identification of dominant optimal HLA-B6-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. Journal Virology. 2000; 74:8541-9. View abstract
  107. Stiehm ER, Fletcher CV, Mofenson L, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, Wara D, Bryson YJ, Starr SE, Petru A, Burchett S . Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type-1 infected children (Pediatric AIDS clinical trials group protocol 273). Journal Infectious Diseases. 2000; 181:548-54. View abstract
  108. Hughes WT, Shenep JL, Rodman JH, Fridland A, Willoughby R, Blanchard S, Purdue L, Coakley DF, Cundy KC, Culnane M, Zimmer B, Burchett S, Read JS . Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The pediatrics AIDS clinical trials group. Antimicrobial Agents Chemotherapy. 2000; 44:1041-6. View abstract
  109. Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A, Culnane M, Read JS, Thomson M, Mohan KM, Shaver A, Robinson CA, Stempien MJ, Burchett SK, Melvin AJ, Borkowsky W, Petru A, Kovacs A, Yogev R, Goldsmith J, McFarland EJ, Spector SA. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The pediatric AIDS clinical trials group. Journal Infectious Dissease . 2000; 182:1616-24. View abstract
  110. The Perinatal Safety Review Working Group . Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. Journal Acquired Immunodeficiency Syndrome . 2000; 25:261-8. View abstract
  111. Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O’Callaghan CA, Kalams SA, McKinney RE Jr, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. Journal Experimental Medicine . 2000; 192:1819-32. View abstract
  112. Samelson R, Shapiro D, Tuomala R, Burchett S, Ciupak G, McNamara J, Pollack H, Read J . HIV vertical transmission rates according to antiretro-viral therapy and viral load during pregnancy among 347 mother-child pairs 1998-99 (PACTG 367). American Journal of Obstetrics and Gynecology. 2000; 182:S97. View abstract
  113. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999 Aug 05; 341(6):394-402. View abstract
  114. Ngo LY, Yogev R, Dankner WM, Hughes WT, Burchett S, Xu J, Sadler B, Unadkat JD. Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. Antimicrob Agents Chemother. 1999 Jun; 43(6):1516-9. View abstract
  115. Burchett SK, Kovacs A, Khoury M, Yong F, Carey V, Smith ME, Mofenson L, Zimmer B, Hawkins E . Preliminary toxicity and tolerability of 4-drug antiretroviral (ARV) therapy with NRTIs, Nevirapine (NVP), Nelfinavir (NFV) and Ritonavir (RTN) in ARV-experienced children with advanced HIV disease. 6th Conference on Retroviruses and Opportunistic Infections. 1999; Chicago. View abstract
  116. Luzuriaga K, Wu H, McManus M, Britto P, Borkowsky W, Burchett S, Smith B, Mofenson L, Sullivan JL. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol. 1999 Jan; 73(1):362-7. View abstract
  117. Luzuriaga K, Wu H, McManus M, Britto P, Borkowsky W, Burchett S, Smith B, Mofenson L, Sullivan JL . Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. Journal of Virology . 1999; 73:362-7. View abstract
  118. Palumbo P and Burchett SK . Diagnosis of HIV Infection and Markers of Disease Progression in Infants. Pediatric AIDS, Pizzo P and Wilfert C, editors. 1998; 67-87. View abstract
  119. Pohl-Koppe A, Burchett SK, Thiele EA, Hafler DA. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol. 1998 Nov 02; 91(1-2):19-27. View abstract
  120. Burchett SK . Viral Infections. Manual of Neonatal Care, Cloherty JP and Stark AR, editors. 1998; 239-71. View abstract
  121. Burchett SK. Congenital Infections. Saunders Manual of Pediatric Practice, Finberg L, editor. 1998; 299-302. View abstract
  122. Burchett SK, Sullivan J, Carey V, Yong F, Culnane M, Mofenson L, Robinson P, Luzuriaga K . Combinations of Didanosine (DDI), Zidovudine (ZDV) and Nevirapine (NVP) can reduce CSF HIV-1 viral load in pediatric patients with advanced HIV disease. 12th World AIDS Conference. 1998; Geneva. View abstract
  123. Garcia PM, Kalish L, Pitt J, Quinn T, Burchett S, Hanson C, Minkoff H, Jackson B, Moye J, Lew J . Maternal human immunodeficiency virus (HIV) RNA level correlates with the risk but does not predict the timing of perinatal transmission. American Journal of Obstetrics and Gynecology. 1998; 178:2S. View abstract
  124. Hitti J, Watts DH, Burchett SK, Schacker T, Selke S, Brown ZA, Corey L. Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol. 1997 Aug; 177(2):450-4. View abstract
  125. Zaknun D, Orav J, Kornegay J, al-Attar I, Fuchs D, Zaknun J, Wachter H, Chatis P, Burchett SK, McIntosh K. Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. J Pediatr. 1997 Jun; 130(6):898-905. View abstract
  126. Frenkel LM, Cowles MK, Shapiro DE, Melvin AJ, Watts DH, McLellan C, Mohan K, Murante B, Burchett S, Bryson YJ, O'Sullivan MJ, Mitchell C, Landers D. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis. 1997 Apr; 175(4):971-4. View abstract
  127. Melvin AJ, Tamura GS, House JK, Hobson AC, Cone RW, Frenkel LM, Burchett S. Lack of detection of human immunodeficiency virus type 1 in the saliva of infected children and adolescents. Arch Pediatr Adolesc Med. 1997 Mar; 151(3):228-32. View abstract
  128. Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, King PD, Johnson EJ, Williams BL, Frenkel LM, Coombs RW. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 01; 14(3):232-6. View abstract
  129. Burchett SK, Carey V, Yong F, Sullivan J, Sulzbacher S, Civitello L, Culnane M, Mofenson L, Siminski S, Robinson P, Luzuriaga K . Virologic activity of Didanosine (DDI), Zidovudine (ZDV) and Nevirapine (NVP) combinations in pediatric subjects with advanced HIV disease (ACTG 245). 5th Conferemce on Retroviruses and Opportunistic Infections. 1997; Chicago(Abst 271):A998. View abstract
  130. Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, King PD, Johnson EJ, Williams BL, Frenkel LM, Coombs RW . Effect of pregnancy and zidovudine therapy on viral load in HIV-I-infected women. Journal Acquired Immune Deficiency Syndrome Human Retrovirology. 1997; 14:232-6. View abstract
  131. Zaknun D, Orav J, Kornegay J, al-Attar I, Fuchs D, Zaknun J, Wachter H, Chatis P, Burchett SK, McIntosh K . Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. Journal Pediatrics. 1997; 130:898-905. View abstract
  132. Frenkel LM, Cowles MK, Shapiro DE, Melvin AJ, Watts DH, McLellan C, Mohan K, Murante B, Burchett S, Bryson YJ, O’Sullivan MJ, Mitchell C, Landers D . Analysis of the maternal components of the AIDS clinical trials group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. Journal Infectious Disease. 1997; 175:971-4. View abstract
  133. McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, Burchett SK. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J. 1996 Dec; 15(12):1087-91. View abstract
  134. Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1996 Dec; 174(6):1162-7. View abstract
  135. Sonnino RE, Pigatt LA, Burchett S, Schrama A, Harris LK, Franson RC. Secretory phospholipase A2 levels in rat small bowel. J Invest Surg. 1996 Jul-Aug; 9(4):313-9. View abstract
  136. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong SJ, Lakeman A, Whitley R. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J. 1996 Mar; 15(3):247-54. View abstract
  137. Pohl-Koppe A, McIntosh K, Burchett SK . Interferon gamma and IL-6 secretion of peripheral blood mononuclear cells is significantly increased in infants with perinatal HIV infection. 3rd National Human Retroviruses and Related Infections Conf. 1996; Washington DC. View abstract
  138. Pohl-Koppe A, Burchett SK, Hafler DA . Functional characterization of autoreactive T-cells in acute disseminated encephalomyelitis. Pediatric Research. 1996; 40:548. View abstract
  139. Jones CA, Burchett SK . Lack of correlation between CMV infection and central neurological compromise in HIV-infected children. 3rd National Human Retroviruses and Related Infections Conference. 1996; Washington DC. View abstract
  140. DeVincenzo JP, Burchett SK . Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral apthhous ulcers. Pediatric Infectious Disease Journal. 1996; 15:465-7. View abstract
  141. Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ . Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National institute of allergy and infectious diseases and infectious diseases collaborative antiviral study group. Journal Infectious Diseases. 1996; 174:1162-7. View abstract
  142. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong SJ, Lakeman A, Whitley R . Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatric Infectious Disease Journal. 1996; 15:247-54. View abstract
  143. Burchett SK, Luzuriaga K, Culnane M, Mofenson L, Carey V, Yong F, Siminski S . Early Toxicity Experience in Combination Therapy of Advanced Pediatric HIV Disease. 35th ICAAC Conference. 1995; San Francisco. View abstract
  144. McIntosh K, Burchett SK. Clearance of HIV--lessons from newborns. N Engl J Med. 1995 Mar 30; 332(13):883-4. View abstract
  145. McIntosh K, Burchett SK . Clearance of HIV: Lessons from newborns. New England Journal Medicine. 1995; 332:883-4. View abstract
  146. Burchett S, Mohan K, Melvin A, Coombs R., Sulzbacher S . Correlates of CNS Disease Progression in Children Vertically-Infected with HIV. 2nd National Human Retroviruses and Related Infections Conference. 1995; Washington DC. View abstract
  147. Burchett SK, Mohan K, Melvin A, Coombs R, Corey L . Defining Pediatric "Rapid HIV Progressors" by Plasma Viremia and Sequential Western Blot. 34th ICAAC Conference. 1994; Orlando. View abstract
  148. Burchett SK. Protective Immunity. Perinatal and Pediatric Pathophysiology, A Clinical Perspective; Gluckman PB and Heymann MA, editors. 1993; 669-73. View abstract
  149. Burchett SK, Gretch D, Fleming J, Dela Rosa C, Watts H, Corey . Maternal hepatitis C (HCV) infection is not a cofactor for enhanced rate of vertical transmission of HIV-I. 9th International Conference AIDS. 1993; Berlin. View abstract
  150. Burchett S . The Placental Barrier to HIV-1 Transmission. The AIDS Reader. 1993; Sept/Oct:163-5. View abstract
  151. Henrard DR, Phillips J, Burchett S, Jackson JB, Kataaha P, Mmiro F, Ndugwa C. Plasma viral load in symptom-free women and vertical transmission of HIV-1. Lancet. 1992 Dec 12; 340(8833):1470-1. View abstract
  152. Watts DH, Burchett SK, Coombs RW, Brown ZA, Corey L . Correlates of vertical transmission of human immunodeficiency virus (HIV). Inf Dis Soc for Obstet-Gynec. 1992. View abstract
  153. Burchett SK, Gretch D, Fleming J, Coombs R, Corey L . Maternal hepatitis C (HCV) infection does not enhance the rate of vertical transmission of HIV. 32nd ICAAC Conference. 1992; Anaheim. View abstract
  154. Ashley RL, Dalessio J, Burchett S, Brown Z, Berry S, Mohan K, Corey L. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest. 1992 Aug; 90(2):511-4. View abstract
  155. Burchett SK, Henrard D, Watts DH, Melvin A, Fleming J, Stamateou J, Coombs RW. Early diagnosis of HIV in infants born to seropositive women. 8th International Conference on AIDS/STD World Congress. 1992; Amsterdam. View abstract
  156. Burchett SK, Corey L, Mohan KM, Westall J, Ashley R, Wilson CB. Diminished interferon-gamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection. J Infect Dis. 1992 May; 165(5):813-8. View abstract
  157. Burchett SK . The role of the placental macrophage in prevention of vertical transmission of HIV. Keystone Conference on Pediatric AIDS. 1992. View abstract
  158. Bratton S, Krane E, Park J, Burchett S . Clostridium septicum infections in children. Pediatric Infectious Diseases Journal. 1992; 11:569-75. View abstract
  159. Burchett SK, Coombs RC, Mohan K, Watts H, Warren K, Corey L. Culture: An early diagnostic tool in infants born to HIV infected women. 31st ICAAC Conference. 1991; Chicago. View abstract
  160. Burchett SK, Coombs RC, Warren K, Watts HD, Wilson C, Corey L . Diminished ability of fetal and neonatal macrophages to support proliferative human immunodeficiency infection. Clin Res. 1991; 39:382A. View abstract
  161. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, Vontver LA, Corey L. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991 May 02; 324(18):1247-52. View abstract
  162. Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S, Starr S, Jacobs R, Powell D, Nahmias A, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14; 324(7):450-4. View abstract
  163. Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14; 324(7):444-9. View abstract
  164. Watts DH, Brown ZA, Tartaglione T, Burchett SK, Opheim K, Coombs R, Corey L. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991 Feb; 163(2):226-32. View abstract
  165. Burchett SK, Coombs R, Stamateou J, Watts HD, Wilson C, Corey L . Comparative susceptibility of neonatal lymphocytes and monocytes to HIV infection. 30th ICAAC. 1990; Atlanta. View abstract
  166. Reiner NE, Ng W, Wilson CB, McMaster WR, Burchett SK. Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. J Clin Invest. 1990 Jun; 85(6):1914-24. View abstract
  167. Watts H, Burchett SK . HIV infection in pregnancy and infancy in AIDS. Diagnosis and treatment. Handbook of AIDS Treatment, Holmes KK, Collier A, Corey L, Handsfield H, editors. 1990; 160-63. View abstract
  168. Reiner NE, NG W, Wilson CB, McMaster WR, Burchett SK . Modulation of in vitro monocyte cytokine responses during infection with Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. Journal Clinical Investigation. 1990; 85:1914-24. View abstract
  169. Burchett S, Coombs R, Chaloupka K, Stamateou J, Wilson C, Mohan K, Corey L , 1989; Montreal. Association between plasma human immunodeficiency virus type-1 (HIV) viremia and clinical class of pediatric HIV infection. 5th International Conference on AIDS. 1989; Montreal. View abstract
  170. Corey L, Brown Z, Burchett S, Wolf ME . The use of antiviral drugs in pregnancy for herpes simplex virus infections. Antiviral Chemotherapy, Mills J, Corey L, editors. 1989; 2:23-36. View abstract
  171. English BK, Burchett SK, English JD, Ammann AJ, Wara DW, Wilson CB. Production of lymphotoxin and tumor necrosis factor by human neonatal mononuclear cells. Pediatr Res. 1988 Dec; 24(6):717-22. View abstract
  172. Burchett SK, Weaver WM, Westall JA, Larsen A, Kronheim S, Wilson CB. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol. 1988 May 15; 140(10):3473-81. View abstract
  173. Tabor DR, Burchett SK, Jacobs RF. Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock. . 1988 Apr; 187(4):408-15. View abstract
  174. Burchett SK, Weaver WM, Westall JA, Larsen A, Kronheim S, Wilson CB. . Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. Journal of Immunology. 1988; 140:3473-81. View abstract
  175. Tabor DR, Burchett SK, Jacobs RF . Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock. Proceedings Society Experimental Biology Medicine. 1988; 187:408-15. View abstract
  176. Glover DM, Brownstein D, Burchett S, Larsen A, Wilson CB. Expression of HLA class II antigens and secretion of interleukin-1 by monocytes and macrophages from adults and neonates. Immunology. 1987 Jun; 61(2):195-201. View abstract
  177. Woody RC, Burchett SK, Steele RW, Sullivan JA, McConnell JR. The role of computerized tomographic scan in the management of Gradenigo's syndrome: a case report. Pediatr Infect Dis. 1984 Nov-Dec; 3(6):595-7. View abstract
  178. Burchett SK, Marmer DJ, Steele RW, Jacobs RF, Elders MJ, Kemp SF. Immunologic profile of growth hormone deficient children before and during growth hormone replacement. Clin Res. 1984; 32(5):A895. View abstract